Supplemental immune globulins in sepsis

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 3, 1999, Pages 341-349

  Werdan, Karl ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cytokines; Endotoxin antibodies; Immune globulins; Sepsis

Indexed keywords

CYTOKINE; ENDOTOXIN; EXOTOXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY;

ADVERSE DRUG REACTION; BLOOD CELL; CELL ACTIVATION; COMPETITIVE INHIBITION; CONFERENCE PAPER; CRITICAL ILLNESS; CYTOKINE RELEASE; DISEASE SEVERITY; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; MORBIDITY; MORTALITY; OPSONIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SERUM BACTERICIDAL ACTIVITY; SUPPLEMENTATION; SURGICAL INFECTION; SURGICAL RISK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

CONTROLLED CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; SEPSIS;

BACTERIA (MICROORGANISMS);

EID: 0032918108     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.1999.057     Document Type: Conference Paper

References (59)

1. Calandra T, Baumgartner JD. Anti-endotoxin therapy. In: Sibbald WJ, Vincent J-L, editors. Clinical trials for the treatment of sepsis (update in intensive care and emergency medicine 19). Berlin, Heidelberg: Springer-Verlag, 1995:237-50.
2. Werdan K, Pilz G. Supplemental immune globulins in sepsis: a critical appraisal. Clin Exp Immunol 1996; 104 [Suppl. 1]:83-90.
3. Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock. A reassessment. Crit Care Med 1997; 24:1095-110.
4. Lee ML, Gale RP, Yap PL. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiencies. Ann Rev Med 1997; 48:93-102.
5. rd ed., 1998:153-90.
6. Zanetti G, Calandra T. Intravenous immunoglobulins and granulocyte colony-stimulating factor for the management of infection in intensive care units. Curr Opin Crit Care 1997; 3:342-7.
7. NIH Consensus conference. Intravenous immunoglobulins: prevention and treatment of disease. J Am Med Assoc 1990; 264:3189-93.
8. Rieben R, Muizert Y, Gerritsen AF, Daha MR. IgM-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood, in press.
9. Dalhoff A. Synergy between acylureidopenicillins and immunogloblin G in experimental animals. Am J Med 1984; 76:91-100.
10. Dalhoff A. In vitro and in vivo effect of immunoglobulin G on the integrity of bacterial membranes. Infection 1985;13 [Suppl 2]:S185.
11. Andersson J, Fehniger Th, Björk L, Andersson U. Intravenous immune globulin has effects on superantigen-induced cytokine synthesis. Infusionsther Transfusionsmed 1996; 23(suppl 4):7-14.
12. Andersson J, Skansen-Saphir U, Sparrelid E, Andersson U. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Clin Exp Immunol 1996; 104(Suppl 1):10-20.
13. Menezes MCS, Benard G, Sato MN, Hong MA, Duarte AJS. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations, Int Arch Allergy Immunol 1997; 114:323-8.
14. Cafiero F, Gipponi M, Bonalumi U, Piccardo A, Sguotti C, Corbetta G. Prophylaxis of infection with intravenous immunoglobulins plus antibiotic for patients at risk for sepsis undergoing surgery for colorectal cancer: results of a randomized, multicenter clinical trial. Surgery 1992; 112:24-31.
15. Kress HG, Scheidewig C, Schmitt H, Silber RE. Reduced incidence of postoperative infections following intravenous application of an IgA- and IgM-enriched immunoglobulin preparation in anergic patients undergoing cardiac surgery. Crit Care Med, in press.
16. Pilz G, Kreuzer E, Werdan K. Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified post-cardiac surgical patients at high-risk for sepsis. Chest 1997; 111:419-26.
17. The Intravenous Immunoglobulin Study Group. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infections. N Engl J Med 1992;327: 234-40.
18. Schedel I, Dreickhausen U, Nentwig B, Höchenschneider M, Rauthmann D, Balikcioglu S, et al. Treatment of Gramnegative septic shock with an immunoglobulin preparation. A prospective, randomized clinical trial. Crit Care Med 1991; 19:1104-13. Letters to the editor: Crit Care Med 1992; 20:1364-5; Crit Care Med 1993; 21:163-5.
19. Schedel I, Dreickhausen U, Nentwig B, Höchenschneider M, Rauthmann D, Balikcioglu S, et al. Treatment of Gramnegative septic shock with an immunoglobulin preparation. A prospective, randomized clinical trial. Crit Care Med 1991; 19:1104-13. Letters to the editor: Crit Care Med 1992; 20:1364-5; Crit Care Med 1993; 21:163-5.
20. Schedel I, Dreickhausen U, Nentwig B, Höchenschneider M, Rauthmann D, Balikcioglu S, et al. Treatment of Gramnegative septic shock with an immunoglobulin preparation. A prospective, randomized clinical trial. Crit Care Med 1991; 19:1104-13. Letters to the editor: Crit Care Med 1992; 20:1364-5; Crit Care Med 1993; 21:163-5.
21. Pilz G, Fateh-Moghadam S, Viell B, Bujdoso O, Döring G, Marget W, et al. Supplemental immunoglobulin therapy in sepsis and septic shock - comparison of mortality under treatment with polyvalent i.v.immunoglobulin versus placebo: protocol of a multicenter, randomized, prospective, double-blind trial. Theor Surg 1993; 8:61-83. Discussion forum: Theor Surg 1994; 9:10-67.
22. Pilz G, Fateh-Moghadam S, Viell B, Bujdoso O, Döring G, Marget W, et al. Supplemental immunoglobulin therapy in sepsis and septic shock - comparison of mortality under treatment with polyvalent i.v.immunoglobulin versus placebo: protocol of a multicenter, randomized, prospective, double-blind trial. Theor Surg 1993; 8:61-83. Discussion forum: Theor Surg 1994; 9:10-67.
23. Rinaldi M, Bardelli F, Rampazzo R, Lusuriello P, Messori A. Effectiveness of immunoglobulins for the prevention of systemic infections - a metaanalysis of 8 clinical studies in premature infants. Clin Drug Invest 1995; 10:328-36.
24. Baumgartner JD. Arguments for the administration of immunglobulins in critically-ill patients. In: Peter K, Lawin P, Bein T, Briegel J, editors. Intensivmedizin 1990 (Intensivmedizin Notfallmedizin Anästhesie, Bd 81). Stuttgart, New York: Thieme-Verlag 1990:152-7.
25. Pilz G, Kreuzer E, Kääb S, Appel R, Werdan K. Early sepsis treatment with immunoglobulins after cardiac surgery in score-identified post-cardiac surgical patients at high risk for sepsis. Chest 1994; 105:76-82.
26. Pilz G, Kääb S, Kreuzer E, Werdan K. Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection 1994; 22:8-17.
27. Pilz G, Fraunberger P, Appel R, Kreuzer E, Werdan K, Walli A, et al. Early prediction of outcome in score-identified, postcardiac patients at high risk for sepsis, using soluble tumor necrosis factor receptor-p55 concentrations. Crit Care Med 1996; 24:596-600.
28. Pilz G, Werdan K. Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock. Infection 1990; 18:253-62.
29. Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S: Effects of early treatment with immunoglobulin uncritical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997; 23:1144-9.
30. Duswald KH, Müller K, Seifert J, Ring J. Wirksamkeit von i.v. Gammaglobulin gegen bakterielle Infektionen chirurgischer Patienten - Ergebnisse einer kontrollierten, randomisierten klinischen Studie. Münch Med Wschr 1980; 122:832-6.
31. Kress HG, Scheidewig C, Engelhardt W, Wallasch H, Elert O. Prediction and prevention, by immunological means, of septic complications after elective cardiac surgery. In: Schlag G, Redl H, editors. Progress in clinical and biological research, vol 308: Second Vienna Shock Forum. New York: Liss 1989:1031-5.
32. Trautmann M, Held TK, Susa M, Karajan MA, Wulf A, Cross AS, et al. Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 1998; 111:81-90.
33. Dickgießer N, Kustermann B. IgG Antikörper gegen das Toxic shock Syndrom Toxin 1 (TSST-1) in Human-Immunglobulinen. Klin Wochenschr 1986; 64:633-5.
34. Dickgießer N, Düzgün F. IgM-Antikörper gegen das Toxic-shock Syndrom Toxin-1 in Humanseren und Human-Immunglobulinen. Klin Wochenschr 1988; 66:7-11.
35. Müller-Werdan U, Pfeifer A, Hübner G, Seliger C, Reithmann C, Rupp H, et al. Partial inhibition of protein synthesis by Pseudomonas exotoxin A deranges catecholamine sensitivity of cultured rat heart myocytes. J Mol Cell Cardiol 1997; 29:799-811.
36. Koch T, Heller S, Weber K, Heller A, Urbaschek R. Effekte von humanem i.v.Immunglobulin auf die Bakterien-Clearance und Granulozytenfunktion bei Endotoxinämie. Anästhesiol Intensivmed Notfallmed Schmerzther 1997; 32:420-5.
37. Fluckiger U, Jones KF, Fischetti VA. Immunoglobulins to group A streptococcal surface molecules decrease adherence to and invasion of human pharyngeal cells. Infection Immunity 1998; 66:97 4-9.
38. Wagner DR, Heinrich D. Influence of polyclonal immunoglobulins on the polymorphonuclear leukocyte response to lipopolysaccharide of Salmonella enteritidis as measured with luminol-enhanced chemiluminescence. Infect Immun 1994; 62: 4320-4.
39. Hill HR, Bathras JM. Protective and opsonic activities of a native, pH 4.25 intravenous immuroglobulin G preparation against common bacterial pathogens. Rev Infect Dis 1986; 8 [Suppl 4]:S396-S400.
40. Garbett ND, Munro CS, Cole PJ. Opsonic activity of a new intravenous immunoglobulin preparation: pentaglobin compared with Sandoglobulin. Clin Exp Immunol 1989; 76:8-12.
41. Christensen RD, Brown MS, Hall DC, Lassiter HA, Hill HR. Effect on neutrophil kinetics and serum opsonic capacity of intravenous administration of immune globulin to neonates with clinical signs of early-onset sepsis. J Pediatr 1991; 118:606-14.
42. Kekow J, Reinhold D, Pap T, Ansorge S. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998; 351:184-5.
43. Van Schaik N, Vermeulen M, Brand A. Intravenous immunoglobulins and transforming growth factor β. Lancet 1998; 351:1288.
44. Mollnes TE, Andreassen IH, Hogasen K, Hack CE, Harboe M. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Molecular Immunol 1997; 34:719-29.
45. Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D, et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma - a randomized, placebo-controlled study. Intensive Care Med 1985; 11:288-94.
46. Just H-M, Metzger M, Vogel W, Pelka RB. Einfluß einer adjuvanten Immunglobulintherapie auf Infektionen bei Patienten einer operativen Intensiv-Therapie-Station - Ergebnisse einer randomisierten kontrollierten Studie. Klin Wochenschr 1986; 64:245-56.
47. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J. Cooperative group of additional immunoglobulin therapy in severe bacterial infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 1987; 65:1132-8.
48. De Simone C, Delogu G, Corbetta G. Intravenous immunoglobulins in association with antibiotics: a therapeutic trial in septic intensive care unit patients. Crit Care Med 1988; 16:23-6.
49. Spannbrucker N, Münch HG, Kunze R, Vogel F. Auswirkungen von Immunglobulin-Substitution bei Sepsis. Intensivmedizin 1987; 24:314.
50. Vogel F. Bewertung der intravenösen IgM-Therapie bei schweren nosokomialen Infektionen (Ergebnis einer kontrollierten randomisierten Studie). In: Deicher H, Schoppe W, editors. Klinisch angewandte Immunologie - Sepsis-therapie mit IgM-angereichertem Immunglobulin. Berlin, Heidelberg, New York, Tokyo: Springer-Verlag, 1988:30-41.
51. Stuttmann R, Hartert M, Coleman JE, Kill H, Germann G, Doehn M. Prophylaxe mit einem Pseudomonas-Immunglobulin bei Brandverletzten. Intensivmedizin 1989; 26 [Suppl1]:130-7.
52. Mao P, Enrichens F, Olivero G, Festa T, Benedetto G, Sciascia C, et al. Early administration of intravenous immunglobulins in the prevention of surgical and post-traumatic sepsis: a double blind randomized clinical trial. Surg Res Comm 1989; 5:93-8.
53. Class I, Schorer R. Adjuvante Therapie mit Pseudomonas-Immunglobulin bei beatmeten Patienten einer operativen Intensivstation. Anästh Intensivther Notfallmed 1989; 24: 167-71.
54. Lehmkuhl P, Pichlmayr I. Sepsis-Therapie mit 5-S-Immunglobulinen. In: Deutsch E, Gadner H, Graninger W, et al, editors. Intensivmedizinisches Seminar, Bd 3: Infektionen auf Intensivstationen. Berlin, Heidelberg, New York: Springer-Verlag 1991: 127-37.
55. Behre G, Ostermann H, Schedel I, Helmerking M, Schiel X, Rothenburger M, et al. Endotoxin concentrations and therapy with polyclonal IgM-enriched immunoglobulins in neutropenic cancer patients with sepsis syndrome: Pilot study and interim analysis of a randomized trial. Antiinfect Drugs Chemother 1995; 13:129-34.
56. Dominioni L, Bianchi V, Imperatori A, Minoia G, Dionigi R. High-dose intravenous IgG fortreatment of severe surgical infections. Dig Surg 1996; 13:430-4.
57. Werdan K, Pilz G, and the SBITS Study Group. Polyvalent immune globulins. Shock 1997; Suppl to vol 7:Abstract 5/1918.
58. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Dionigi R, Acquarolo A, et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126:236-40.
59. Thomson A, Sills J, Hart CA, Harris F: Anti-endotoxin therapy for fulminant meningococcal septicaemia: pilot study. Arch Dis Child 1989; 64:1217-8.